These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 28746811)

  • 1. The acute effects of different spironolactone doses on cardiac function in streptozotocin-induced diabetic rats.
    Vranic A; Simovic S; Ristic P; Nikolic T; Stojic I; Srejovic I; Zivkovic V; Jakovljevic V; Djuric D
    Can J Physiol Pharmacol; 2017 Nov; 95(11):1343-1350. PubMed ID: 28746811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Working heart function in diabetes is not improved by spironolactone treatment.
    Verma S; Yuen VG; Badiwala M; Anderson TJ; McNeill JH
    Can J Physiol Pharmacol; 2003 May; 81(5):493-6. PubMed ID: 12774856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats.
    Miric G; Dallemagne C; Endre Z; Margolin S; Taylor SM; Brown L
    Br J Pharmacol; 2001 Jul; 133(5):687-94. PubMed ID: 11429393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of zofenopril on cardiac function and pro-oxidative parameters in the streptozotocin-induced diabetic rat heart.
    Ristic P; Srejovic I; Nikolic T; Stojic I; Ristic D; Zivkovic V; Jakovljevic VL
    Mol Cell Biochem; 2017 Feb; 426(1-2):183-193. PubMed ID: 27882442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a novel molybdenum ascorbate complex on ex vivo myocardial performance in chemical diabetes mellitus.
    Broderick TL; Bailey J; Gagnon KJ; Lord SJ; Vogels CM; Westcott SA
    Drugs R D; 2006; 7(2):119-25. PubMed ID: 16542058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation into the cardiac effects of spironolactone in the experimental model of type 1 diabetes.
    Goyal BR; Solanki N; Goyal RK; Mehta AA
    J Cardiovasc Pharmacol; 2009 Dec; 54(6):502-9. PubMed ID: 19738487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose copper infusion into the coronary circulation induces acute heart failure in diabetic rats: New mechanism of heart disease.
    Cheung CC; Soon CY; Chuang CL; Phillips AR; Zhang S; Cooper GJ
    Biochem Pharmacol; 2015 Sep; 97(1):62-76. PubMed ID: 26208785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of propionyl-L-carnitine on cardiac dysfunction in streptozotocin-diabetic rats.
    Terada R; Matsubara T; Koh N; Nakamura J; Hotta N
    Eur J Pharmacol; 1998 Sep; 357(2-3):185-91. PubMed ID: 9797035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular effects of secretin in intact rats versus rats with streptozotocin-induced diabetes mellitus.
    Sitniewska E; Wiśniewska RJ
    Pol J Pharmacol; 1999; 51(2):131-6. PubMed ID: 10425641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of aldosterone and spironolactone on the isolated perfused rat heart.
    Moreau D; Chardigny JM; Rochette L
    Pharmacology; 1996 Jul; 53(1):28-36. PubMed ID: 8875599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts.
    Takeda M; Tatsumi T; Matsunaga S; Hayashi H; Kimata M; Honsho S; Nishikawa S; Mano A; Shiraishi J; Yamada H; Takahashi T; Matoba S; Kobara M; Matsubara H
    Hypertens Res; 2007 May; 30(5):427-37. PubMed ID: 17587755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin improves cardiac function in isolated streptozotocin-diabetic rat hearts.
    Verma S; McNeill JH
    Am J Physiol; 1994 Feb; 266(2 Pt 2):H714-9. PubMed ID: 8141372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of spironolactone on systolic blood pressure in experimental diabetic rats.
    Liu YJ; Nakagawa Y; Toya K; Wang Y; Saegusa H; Nakanishi T; Ohzeki T
    Kidney Int; 2000 May; 57(5):2064-71. PubMed ID: 10792625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats.
    Fujisawa G; Okada K; Muto S; Fujita N; Itabashi N; Kusano E; Ishibashi S
    Kidney Int; 2004 Oct; 66(4):1493-502. PubMed ID: 15458443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of alloxan- and streptozotocin-induced diabetes on isolated rat heart responsiveness to carbachol.
    Vadlamudi RV; McNeill JH
    J Pharmacol Exp Ther; 1983 May; 225(2):410-5. PubMed ID: 6341541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential beneficial as well as detrimental effects of chronic treatment with lisinopril and (or) spironolactone on isolated hearts following low-flow ischemia in normal and infarcted rats.
    Rochetaing A; Chapon C; Marescaux L; Le Bouil A; Furber A; Kreher P
    Can J Physiol Pharmacol; 2003 Sep; 81(9):864-72. PubMed ID: 14614522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
    Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
    Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus.
    Guo C; Martinez-Vasquez D; Mendez GP; Toniolo MF; Yao TM; Oestreicher EM; Kikuchi T; Lapointe N; Pojoga L; Williams GH; Ricchiuti V; Adler GK
    Endocrinology; 2006 Nov; 147(11):5363-73. PubMed ID: 16901964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute effects of nandrolone decanoate on cardiodynamic parameters in isolated rat heart.
    Nikolic TR; Zivkovic VI; Srejovic IM; Radovanovic DS; Jeremic NS; Jevdjevic MD; Djuric DM; Jakovljevic VL
    Can J Physiol Pharmacol; 2016 Oct; 94(10):1048-1057. PubMed ID: 27322017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose enalapril reduces angiotensin II and attenuates diabetic-induced cardiac and autonomic dysfunctions.
    Malfitano C; De Angelis K; Fernandes T; Wichi RB; Rosa K; Pazzine M; Mostarda C; Ronchi FA; Oliveira EM; Casarini DE; Irigoyen MC
    J Cardiovasc Pharmacol; 2012 Jan; 59(1):58-65. PubMed ID: 21921804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.